Aridis Pharmaceuticals Inc. (NASDAQ:ARDS) does about 122.89K shares in volume on a normal day but saw 2764320 shares change hands in Monday trading. The company now has a market cap of 26.37M USD. Its current market price is $1.17, marking a decrease of -0.85% compared to the previous close of $1.18. The 52 week high reached by this stock is $2.94 whilst the lowest price level in 52 weeks is $0.68. The script in recent trading has seen the stock touch a high of $1.45 and a low of $1.15.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
Aridis Pharmaceuticals Inc. (ARDS) has a 20-day trading average at $1.2223 and the current price is -60.20% off the 52-week high compared with 71.43% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.0477 and its 200-day simple moving average is $1.2548. If we look at the stock’s price movements over the week, volatility stands at 19.75%, which decreases to 17.54% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 49.06 to suggest the stock is neutral.
2 analysts observing the Aridis Pharmaceuticals Inc. (ARDS) stock have set the 12-month price targets for the company’s shares at between $2.00 and $19.00. The consensus objective for the share price is $10.50, suggesting that the stock has a potential upside of 88.86% over the period. The median price target is 88.86% away from the current levels at $10.50.
FactSet Research has provided data showing that 2 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 2 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Moderate Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on February 19, 2020 when ROTH Capital initiated the stock to “Buy” and issued a price target of $18.
The current price level is -3.73%, 12.22%, and -6.92% away from its SMA20, SMA50, and SMA200 respectively, with the ARDS price moving below the 50-day SMA on January 23. Aridis Pharmaceuticals Inc. (ARDS) stock is down -8.24% over the week and 15.84% over the past month. Its price is -0.85% year-to-date and -12.03% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/29/2022, with the company’s earnings per share (EPS) of -$0.45 below consensus estimates by -$0.39. ARDS’s earnings per share are forecast to grow by 79.70% this year and -12.80% over next year. Expected sales for next quarter are $20.57 million, which analysts say will come at $29.53 million for the current fiscal year and next year at $19.07 million. In addition, estimates put the company’s current quarterly revenue at an average of $7.47 million.
To reach the target analysts have set, the stock logically needs to grow 88.86 percent from here.
Outstanding shares total 17.70M with insiders holding 12.88% of the shares and institutional holders owning 8.07% of the company’s common stock. The company has a return on investment of 591.40% and return on equity of 134.90%. The beta has a value of 1.21. Price to sales ratio is 9.09.
Vanguard Extended Market Index Fu raise their holdings by 0.26% in the company over the course of the most recent quarter. It now holds a 0.62% position in Aridis Pharmaceuticals Inc. thanks to 0.13 million shares amounting to $0.15 million.
